Jubilant Ingrevia Ltd (JUBLINGREA) is currently trading at 607.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Jubilant Ingrevia is a vertically integrated speciality chemicals and life‑science ingredients manufacturer operating five Indian manufacturing facilities, producing vitamin B3 (niacinamide), picolinates, chemical intermediates, CDMO services and nutrition premixes, and serving 400+ global customers across pharmaceuticals, agrochemicals, nutrition, and specialty industries. Q1 FY27 delivered a strong start with consolidated revenue of INR1,300 crore (up 25% YoY), EBITDA of INR209 crore (up 36% YoY) and PAT of INR106 crore (up 41% YoY), driven by specialty chemicals, nutrition and a rebound in chemical intermediates with improved realizations and volume growth. The company has an expanding CDMO/fine chemicals funnel — management cites 100+ molecules and INR3,500+ crore peak potential, with 25+ confirmed molecules and recent commercialisation of a large agro CDMO contract that began supplies in March and is scaling volumes. Operationally, Jubilant Ingrevia is progressing multiple capacity additions including a multi‑purpose plant due by year‑end, a dedicated semiconductors clean room and R&D effort, and integration of Remidex to scale human nutrition premixes, all supporting the Pinnacle strategic agenda. Management remains cautiously optimistic while maintaining FY27 EBITDA guidance of INR750–800 crore, citing resilient demand, pricing improvement in key segments and targeted INR100 crore lean savings, but flags raw material price volatility and customer volume timing as risks.

Over the past 52 weeks, Jubilant Ingrevia Ltd has traded between a low of ₹535.30 and a high of ₹794.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Jubilant Ingrevia Ltd has a market capitalization of approximately 9,583.95. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Jubilant Ingrevia Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 31.05 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 9,583.95 Cr, Jubilant Ingrevia Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Jubilant Ingrevia Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Jubilant Ingrevia Ltd is 31.05. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Shareholders approved a final dividend of ₹2.50 per equity share for FY26 at the AGM held on August 26, 2026.

Jubilant Ingrevia has entered into a binding agreement to acquire a 40% strategic equity stake in Zettaone Technologies India.

Consolidated revenue from operations was Rs 1,300.3 crore in Q1 FY27, up about 25% year-on-year and about 10% quarter-on-quarter.

Uniresearch estimates Q1 FY27 revenue at ₹1,052 crore, compared with ₹1,038 crore in Q1 FY26, implying 1.4% year-on-year growth.